Oncology

Latest News

Highlights From ACCC Fall 2024
ICYMI: Highlights From ACCC Fall 2024

January 1st 2025

Top content from the Association of Cancer Care Centers (ACCC) fall conference included topics on patient participation, new cancer care programs, prior authorization processing, and more.

Top 5 Most-Read Oncology Articles of 2024
Top 5 Most-Read Oncology Content of 2024

December 25th 2024

Most Popular Articles of 2024 in Evidence-Based Oncology
Most Popular Articles of 2024 in Evidence-Based Oncology

December 23rd 2024

Highlights From ASCO 2024
ICYMI: Highlights From ASCO 2024

December 21st 2024

chemotherapy | Image credit: Penn Medicine
The High Cost of Shortages of Low-Cost Chemotherapy

December 19th 2024

Join this panel as they discuss treatment for metastatic NSCLC patients without driver mutations.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Outcomes From the RESONATE 2 and HELIOS Trials - Clinical Impact
July 18th 2016

Outcomes From the RESONATE 2 and HELIOS Trials - Clinical Impact

Value of Real-World Data in CLL Treatment
July 18th 2016

Value of Real-World Data in CLL Treatment

Looking to the Future in CLL Treatments
July 18th 2016

Looking to the Future in CLL Treatments

Safety and Efficacy Considerations in CLL
July 18th 2016

Safety and Efficacy Considerations in CLL

Safety of CLL Treatment and Reimbursement
July 18th 2016

Safety of CLL Treatment and Reimbursement

The Changing Treatment Paradigm in CLL
July 18th 2016

The Changing Treatment Paradigm in CLL

How Do Payers Assess Value of Treatments in CLL?
July 18th 2016

How Do Payers Assess Value of Treatments in CLL?

Expanding Options in Treating CLL
July 18th 2016

Expanding Options in Treating CLL

Treatment Options for Older Patients With CLL
July 18th 2016

Treatment Options for Older Patients With CLL

Patient Selection for Treatment With Ibrutinib in CLL
July 18th 2016

Patient Selection for Treatment With Ibrutinib in CLL

RESONATE-2 Trial: Safety and Efficacy Updates
July 18th 2016

RESONATE-2 Trial: Safety and Efficacy Updates

Efficacy and Safety Considerations to Improve the Value of Treatment in CLL
July 18th 2016

Efficacy and Safety Considerations to Improve the Value of Treatment in CLL

Impact of Novel Agents on Coverage Decisions in CLL
July 18th 2016

Impact of Novel Agents on Coverage Decisions in CLL

Factors That Influence Up-front Therapy and Sequencing in CLL
July 18th 2016

Factors That Influence Up-front Therapy and Sequencing in CLL

Combination Treatments in CLL
July 18th 2016

Combination Treatments in CLL

Flexibility in Treatment Options for CLL
July 18th 2016

Flexibility in Treatment Options for CLL

Pathophysiology, Prognostic Factors, and Potential Risks That Influence Treatment in CLL
July 18th 2016

Pathophysiology, Prognostic Factors, and Potential Risks That Influence Treatment in CLL

Impact of Major Trials on CLL Treatment
July 18th 2016

Impact of Major Trials on CLL Treatment

Health Plans Encourage Use of Diagnostic Tests in CLL
July 18th 2016

Health Plans Encourage Use of Diagnostic Tests in CLL

Increased Use of Targeted Therapies in CLL
July 18th 2016

Increased Use of Targeted Therapies in CLL

Pathophysiology and Treatment Landscape of CLL
July 18th 2016

Pathophysiology and Treatment Landscape of CLL

Site Logo
July 18th 2016

UIC Study Supports Use of Adjuvant Chemotherapy in Stage II Colon Cancer

Surabhi Dangi-Garimella, PhD
According to the study published in Cancer, adjuvant chemotherapy in patients with early stage colon cancer results in clinically relevant improvement in overall survival.
Site Logo
July 18th 2016

Understanding and Mitigating the Financial Burden of Cancer Patients

Surabhi Dangi-Garimella, PhD
Drug prices have developed into the fastest growing segment of healthcare costs and are a significant burden on the patient's wallet, in addition to the cost of healthcare services. An Education Session at the annual meeting of the American Society of Clinical Oncology discussed potential solutions to ease this problem.
Site Logo
July 18th 2016

ASCO Study Finds Daratumumab Could Be Economical Over Pomalidomide—Dexamethasone in MM

Surabhi Dangi-Garimella, PhD
A poster presented at the annual meeting of the American Society of Clinical Oncology evaluated the cost per median month of survival for daratumumab and other novel treatments for multiple myeloma.
This Week in Managed Care: July 16, 2016
July 16th 2016

This Week in Managed Care: July 16, 2016

The top stories in managed care this week included coverage of JAMA’s special issue on healthcare transformation under the ACA, changes in the proposed 2017 Physician Fee Schedule promoting value-based care, and more.
Site Logo
July 15th 2016

Disparity in Bone Density Assessment in Older Women Treated With AI for Breast Cancer

Surabhi Dangi-Garimella, PhD
Despite their known risk, only half the women over 85 years of age in a cohort being evaluated had their baseline bone density tested prior to initiating treatment.
Site Logo
July 15th 2016

Aggressive Cancer Care Widely Used Among Patients at the End of Life

Cate Douglass
Many patients, 65 years or younger, are still receiving aggressive cancer treatment in their final months of life despite Choosing Wisely recommendations encouraging symptom-directed palliative care.
Site Logo
July 15th 2016

Lessons to Learn From the NICE Cancer Care Model

Surabhi Dangi-Garimella, PhD
On the first day of the annual meeting of the American Society of Clinical Oncology, healthcare experts from the United States, Canada, and the United Kingdom, compared and contrasted the care models that are widely adopted in each nation.
Dr Debra Patt Breaks Down Rising Cancer Care Costs
July 15th 2016

Dr Debra Patt Breaks Down Rising Cancer Care Costs

Although cancer care costs are rising, it is proportional to the total utilization of healthcare resources and spending growth is happening more in areas that have seen innovation, explained Debra Patt, MD, MPH, MBA, director of public policy at Texas Oncology.
Site Logo
July 14th 2016

NEJM Study First to Identify Mutations Responsible for Relapse in PD-1 Inhibitor—Treated Melanoma

Surabhi Dangi-Garimella, PhD
Loss-of-function mutations in Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2), deletion of the wild-type allele of JAK1 or JAK2, and truncation in the antigen-presenting protein beta-2-microglobulin gene were found responsible for lack of response to interferon gamma.
<1
...
9293949596979899100
...
181>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo